Trianni mouse model tapped for HIV vaccine research

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/unoL)
(Image: Getty/unoL)

Related tags: License, Hiv, Research, CAR-T, Monoclonal antibodies

Trianni and San Diego Biomedical Research Institute enter license agreement for the use of the Trianni Mouse in HIV vaccine research.

Trianni Mouse, a transgenic mouse R&D platform for the discovery of fully human monoclonal antibodies (mAb) will be used by San Diego Biomedical Research Institute as the research institute to support its HIV vaccine research efforts.

Trianni CEO Matthias Wabl explained that the human antibody platform is powered by a mouse that when injected with a therapy target, produces human antibodies. Depending on the terms of the license, the mice are delivered to the licensee that isolates from the mice antibodies that are drug candidates, he told us

Joanna Davies, president and CEO at SDBRI, said in a statement, “We are extremely hopeful that the Trianni Mouse will accelerate our progress towards developing a successful HIV vaccine.”

The Trianni Mouse model has been used in license agreements to advance drug discovery. Juno Therapeutics​ entered an agreement with Trianni in 2017 to use the mouse model to identify full-human binders for conversion to chimeric antigen receptors (CAR) as part of its engineered T cell programs.

No financial details of the agreement were disclosed. 

Related news

Show more

Related products

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more